Variable | Rebiopsy | ||
---|---|---|---|
(+) | (−) | ||
T790M mutation | |||
Positive (n = 29) | Negative (n = 17) | Unknown (n = 7) | |
Sex | |||
Male | 11 | 3 | 3 |
Female | 18 | 14 | 4 |
Age (years) median (range) | 74 (42 - 86) | 72 (38 - 89) | 70 (59 - 82) |
Histology | |||
Adenocarcinoma | 27 | 17 | 7 |
others | 2 | 0 | 0 |
EGFR mutation at initial diagnosis | |||
Exon 19 deletion | 21 | 6 | 1 |
L858R | 8 | 9 | 5 |
L861Q | 0 | 1 | 0 |
Exon 20 insertion | 0 | 1 | 0 |
Compound mutation | 0 | 0 | 1 |
Smoking status | |||
Never | 18 | 13 | 3 |
Past | 8 | 1 | 2 |
Current | 3 | 3 | 2 |
ECOG performance status | |||
0 | 20 | 12 | 3 |
1 | 8 | 5 | 2 |
2 | 1 | 0 | 1 |
3 | 0 | 0 | 1 |
Stage at initial diagnosis | |||
IA - IIIC | 10 | 3 | 3 |
IVA - IVB | 19 | 14 | 4 |
Surgical treatment | |||
No | 13 | 6 | 3 |
Yes | 16 | 11 | 4 |
Radical Radiotherapy | |||
No | 27 | 16 | 6 |
Yes | 2 | 1 | 1 |
Chemotherapy during treatment | |||
No | 8 | 6 | 6 |
Yes | 21 | 11 | 1 |
Reason for termination of TKIs | |||
Ongoing | 1 | 5 | 3 |
Adverse events | 0 | 1 | 3 |
Tumor growth | 14 | 3 | 0 |
New lesions | 14 | 8 | 1 |
“CEA at progression” / “nadir CEA”; median (range) | 3.1 (1.1–170) | 2.5 (1.3–7.88) | 2.0 (0.5–3.57) |
nadir CEA (ng/mL); median (range) | 3.0 (0.8–36.9) | 2.2 (1.0–78.9) | 45.6 (1.4–198) |
Medical Drugs at TKI naïve line | |||
Gefitinib | 11 | 2 | 0 |
Erlotinib | 16 | 10 | 6 |
Afatinib | 2 | 5 | 1 |